Rekombinanter CEACAM5 (Tusamitamab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter CEACAM5 (Tusamitamab Biosimilar) Antikörper (ABIN7795147)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Tusamitamab Biosimilar, Human CEACAM5 Monoclonal Antibody
-
Produktmerkmale
- What is tusamitamab biosimilar research grade? Tusamitamab is a humanized IgG1-kappa monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) which is overexpressed in tumors including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and is an attractive target for therapies based on CAR-T cell or/and ADCs. Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC) combining a humanized monoclonal antibody and a potent cytotoxic maytansinoid derivative (DM4) inhibiting microtubule assembly. Tusamitamab biosimilar uses the same protein sequences as the therapeutic antibody tusamitamab.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human CEACAM5
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- CEACAM5 (Tusamitamab Biosimilar)
-
Andere Bezeichnung
- Tusamitamab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-